Welcome to our dedicated page for Ibio news (Ticker: IBIO), a resource for investors and traders seeking the latest updates and insights on Ibio stock.
iBio, Inc. (NASDAQ: IBIO) is an AI-driven biotechnology company developing precision antibody therapies for cardiometabolic diseases, obesity, cancer and other hard-to-treat conditions. The IBIO news feed on Stock Titan aggregates company press releases and other coverage so readers can follow how the business and its preclinical pipeline are evolving over time.
Recent news highlights iBio’s focus on obesity and cardiometabolic disease, including preclinical data for its Activin E antibody candidate IBIO-610 and its long-acting anti-myostatin antibody IBIO-600. The company has reported fat-selective, GLP‑1‑synergistic weight loss in diet-induced obesity mouse models, non-human primate pharmacokinetic data suggesting extended half-life and potential for infrequent dosing, and early evidence that its programs may help preserve lean mass in combination with GLP‑1 therapies. Updates also cover presentations at scientific and investor conferences such as ObesityWeek, PEGS Europe and healthcare-focused investment conferences.
Investors tracking IBIO news will also see announcements about financings, including underwritten public offerings, warrant transactions and private placements with institutional investors, along with disclosures on how proceeds are intended to support preclinical cardiometabolic programs and other pipeline assets. Regulatory and corporate developments reported via Form 8‑K, such as Nasdaq listing compliance notices, annual meeting results and updated corporate presentations, provide additional context on governance and capital markets activity.
By following this IBIO news page, readers can monitor new preclinical data, conference participation, financing transactions and key SEC-reported events that shape iBio’s progress as a preclinical-stage, AI-enabled antibody developer.
iBio, Inc. (NYSE AMERICAN:IBIO) has announced it regained compliance with NYSE American listing standards as of October 1, 2020. This follows the company's resolution of a previous deficiency related to market capitalization. CEO Tom Isett emphasized that the company’s new strategic plan has strengthened its financial position and value drivers. iBio aims to leverage its proprietary technologies, including the FastPharming® System, to develop biological medicines for respiratory diseases, including COVID-19.
iBio has signed a Master Services Agreement with Safi Biosolutions to evaluate the use of its FastPharming System in producing proteins for blood cell therapies. This collaboration aims to enhance the bioprocessing of red blood cells and neutrophil therapies, which are critical for trauma and chemotherapy recovery. Additionally, iBio will invest $1.5 million in Safi via a convertible promissory note, boosting its role in innovative blood products development.
iBio has announced that its candidate IBIO-201, a LicKM™-subunit vaccine, showed superior efficacy in inducing anti-spike neutralizing antibodies in preclinical studies compared to IBIO-200. The company plans to advance IBIO-201 into toxicity studies and continue evaluating IBIO-200 as part of its COVID-19 vaccine development program. Collaboration with IDRI and the Texas A&M University System is ongoing to further characterize and test IBIO-201. iBio has capabilities for clinical manufacturing at its facility in Texas.
iBio, Inc. (NYSE AMERICAN: IBIO) announced an exclusive worldwide license with Planet Biotechnology for the development of ACE2-Fc, a therapeutic candidate targeting COVID-19. The ACE2-Fc protein acts as a decoy to block SARS-CoV-2 from infecting cells. iBio aims to leverage its FastPharming® System for rapid product development and has the capability to manufacture at clinical and commercial scales. Planet is eligible for milestone payments as development progresses, highlighting the potential collaboration in addressing the pandemic.
iBio Inc. (NYSE AMERICAN: IBIO) provided a promising update on its COVID-19 vaccine candidate, IBIO-201. Preclinical studies demonstrated its ability to generate immune responses against SARS-CoV-2, with increasing antibody titers observed over 42 days. The company is collaborating with Texas A&M University System to conduct additional testing focused on neutralizing titers and immune profiling. iBio highlighted its capability to advance vaccine candidates rapidly, leveraging its FastPharming Facility for scale-up production.
iBio, Inc. (NYSE AMERICAN:IBIO) will be added to the Russell 2000 and Russell 3000 indexes effective June 29, 2020. This addition signals significant progress in the company’s journey to enhance shareholder value. CEO Tom Isett highlighted recent achievements, including the launch of the FastGlycaneering Development Service™ and collaborations for a bio-better rituximab. Furthermore, iBio is advancing COVID-19 vaccine candidates, with preclinical data expected in Q3-2020, showcasing potential future milestones for the company.
iBio has been selected by IBM Watson Health to receive 18 months of complimentary use of the IBM Clinical Development (ICD) solution, aimed at facilitating the company's COVID-19 vaccine trials. This recognition highlights iBio's potential in vaccine development, among hundreds of applicants. Data from preclinical studies of the COVID-19 vaccine candidates IBIO-200 and IBIO-201 is expected in Q3-2020. The partnership is anticipated to accelerate clinical trial processes and enhance data management efficiency.
iBio announced the initiation of preclinical immunization studies for its second COVID-19 vaccine, IBIO-201, featuring a subunit vaccine combining SARS-CoV-2 spike protein antigens and the proprietary LicKM booster technology. This development could enhance immune response and manufacturing capacity. iBio's plant-based FastPharming System™ facilitates scalable production, potentially yielding hundreds of millions of doses. The vaccine's efficacy is backed by prior research, indicating the promise of LicKM technology in achieving prolonged immunity.